Want to see CBLL full AI Analyst Report?
CBLL Stock Chart & Stats
$16.91
$1.22(7.21%)
At close: 4:00 PM EDT
$16.91
$1.22(7.21%)
Day’s Range― - ―
52-Week Range$10.85 - $24.33
Previous Close$18.13
Volume442.39K
Average Volume (3M)265.67K
Market Cap
$669.31M
Enterprise Value$571.30
Total Cash (Recent Filing)$141.18M
Total Debt (Recent Filing)$22.12M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Aug 10, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.63
Shares Outstanding37,942,700
10 Day Avg. Volume244,220
30 Day Avg. Volume265,666
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)5.16
Price to Sales (P/S)9.00
P/FCF Ratio-19.28
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$28.50Price Target Upside68.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.71
Revenue Forecast (FY)$113.98M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue Growth And Account AdoptionCeribell’s consistent double‑digit top‑line growth and the largest single‑quarter account adds since IPO indicate durable commercial traction in acute care. Broadening hospital adoption supports recurring consumable and subscription usage, creating a expanding install base that drives repeat revenue over multiple years.
Very High And Sustainable Gross MarginsGross margins in the high‑80% range reflect strong unit economics and pricing power for Ceribell’s point‑of‑care EEG. Persistently high margins provide structural durability: as utilization and subscription uptake scale, the company can leverage fixed costs to improve operating leverage and convert revenue growth into eventual profit.
Solid Liquidity And Manageable LeverageA cash balance north of $140M with relatively low total debt (debt/TTM equity ~0.16) gives Ceribell runway to fund commercialization, manufacturing shifts, and regulatory initiatives without immediate refinancing. Manageable leverage reduces near‑term financial stress as the company scales toward breakeven.
Bears Say
Negative Operating Cash FlowSustained negative operating cash flow of roughly $49M TTM shows the business currently consumes cash to fund growth rather than generate it. This structural cash burn increases dependence on external financing, which can dilute shareholders or constrain strategic options until operations move to positive cash generation.
Deep Negative Net MarginsDespite strong revenue expansion, Ceribell’s net margin near -64% indicates the company remains far from profitability. Persistent heavy losses increase the risk of continued equity dilution, compress returns on invested capital, and mean management must materially narrow losses to deliver sustainable shareholder value.
Rising Operating Expenses And Litigation CostsOperating expense growth and elevated one‑time or recurring litigation charges materially widen near‑term losses. Higher S&M and R&D to drive adoption are necessary, but persistent elevated G&A/litigation can structurally delay EBITDA breakeven and consume cash that would otherwise fund commercial expansion.
Ceribell, Inc. News
CBLL FAQ
What was Ceribell, Inc.’s price range in the past 12 months?
Ceribell, Inc. lowest stock price was $10.85 and its highest was $24.33 in the past 12 months.
What is Ceribell, Inc.’s market cap?
Ceribell, Inc.’s market cap is $669.31M.
When is Ceribell, Inc.’s upcoming earnings report date?
Ceribell, Inc.’s upcoming earnings report date is Aug 10, 2026 which is in 8 days.
How were Ceribell, Inc.’s earnings last quarter?
Ceribell, Inc. released its earnings results on May 11, 2026. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.391 by -$0.129.
Is Ceribell, Inc. overvalued?
According to Wall Street analysts Ceribell, Inc.’s price is currently Undervalued.
Does Ceribell, Inc. pay dividends?
Ceribell, Inc. does not currently pay dividends.
What is Ceribell, Inc.’s EPS estimate?
Ceribell, Inc.’s EPS estimate is -0.47.
How many shares outstanding does Ceribell, Inc. have?
Ceribell, Inc. has 37,942,700 shares outstanding.
What happened to Ceribell, Inc.’s price movement after its last earnings report?
Ceribell, Inc. reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.391. Following the earnings report the stock price went down -16.5%.
Which hedge fund is a major shareholder of Ceribell, Inc.?
Currently, no hedge funds are holding shares in CBLL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ceribell, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.50 (68.54% Upside)
$28.50 (68.54% Upside)
Blogger Sentiment
Bullish
CBLL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 17.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.74%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-16.58%
Trailing 12-Months
Company Description
Ceribell, Inc.
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.
CBLL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial momentum and robust top-line growth (29% YoY revenue, record account additions, high 87% gross margin), alongside several strategic milestones (neonate/pediatric launches, delirium pilot with FDA clearance, favorable NTAP proposal, LVO Breakthrough designation) and a healthy cash position. Offsetting these positives are elevated operating expenses (+36% YoY), significant near-term litigation costs ($5.6M in Q1), a wider net loss ($19.7M), and continued adjusted EBITDA losses. Given the combination of accelerating revenue/market expansion and manageable but notable near-term expense pressures, the tone is constructive with near-term investment-driven profitability headwinds.View all CBLL earnings summariesCBLL Stock 12 Month Forecast
Average Price Target
$28.50
▲(68.54% Upside)
Technical Analysis
Ownership Overview
26.50% Insiders
25.95% Mutual Funds
6.78% Other Institutional Investors
33.10% Public Companies and
Individual Investors